Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Zeffix Approved In Taiwan For Chronic Hepatitis B LAVAL, QC -- November 1, 1999 -- The Department of Health in Taiwan has approved BioChem Pharma Inc.’s Zeffix (lamivudine), the first effective oral treatment for chronic hepatitis B discovered by BioChem Pharma and marketed by Glaxo Wellcome. Zeffix is indicated for the treatment of patients, 16 years of age or older, with chronic hepatitis B and evidence of viral replication. In addition to significantly reducing liver inflammation, Zeffix has been shown in clinical trials to produce, after three years of continued treatment, seroconversion(x) rates of 65 percent in patients with active liver disease(xx) and 40 percent in the overall patient group. According to World Health Organization estimates, approximately 350 million people around the world are long-term (chronic) carriers of the hepatitis B virus (HBV), including more than 2.5 million people in Taiwan. Zeffix is already available in a number of countries including the US (as Epivir- HBV), Canada (as Heptovir), South Korea, the European Union and was recently launched for sale in China (as Heptodin). Under agreement, BioChem Pharma receives royalties from Glaxo Wellcome on sales of lamivudine for use in both HIV/AIDS (3TC/Epivir/Combivir) and HBV (Zeffix/Epivir-HBV/Heptovir/Heptodin). Glaxo Wellcome has the right to develop, manufacture and sell lamivudine worldwide, except in Canada, where BioChem Pharma and Glaxo Wellcome have formed a commercialization partnership. Epivir, 3TC, Combivir, Zeffix, Epivir-HBV, Heptovir and Heptodin are trademarks of the Glaxo Wellcome Group of Companies. Legend: (x) Loss of hepatitis B virus antigen and gain of antibodies against the virus in the blood - an indicator of long-lasting improvement of the disease. (xi) Greater than twice the upper limit of the normal level of a liver enzyme called ALT (alanine aminotransferase). Related Links: Zeffix (lamivudine) and BioChem Pharma Inc. E-mail this page to a friend or colleague! To print, use this version